Psoriasis Therapeutics in Asia-Pacific Markets Discussed by GBI Research in Insightful Report Available at

16 Jun 2015 • by Natalie Aster

LONDON – As of 2014, the psoriasis therapeutics market in the Asia-Pacific region reached a value of USD 690 million.

The psoriasis treatment landscape is characterized by a high level of complexity. Over two thirds of patients belong to the mild-or-moderate category, with topical drugs being used for their treatment.  If a case is severe, non-steroidal drugs (e.g. acitretin) are used as a first-line treatment. However, they cannot be used for a long period of time due to toxicity concerns.  Biologics (e.g. TNF inhibitors) are at present used a second-line treatment. However, their market share is expected to increase in the years to come given growing awareness of their effectiveness.

The Asia-Pacific market is forecast to grow at 8.4 percent CAGR over the period 2014-2021. It is expected to amount to USD 1.2 billion in 2021 in value terms.

In-demand study “Psoriasis Therapeutics in Asia-Pacific Markets to 2021” prepared by GBI Research offers a thorough analysis of psoriasis therapeutics in the Asia-Pacific region. The research report provides a bird’s eye view of the marketplace. It insightfully examined drugs that are marketed at present and compares them in terms of efficacy and safety. The study casts light on the pipeline for psoriasis and focuses on pipeline drug clinical trials. The report investigates factors driving market growth and posing a challenge to it. It explores the competitive landscape and unveils latest deals and other activities. Future market outlook can be found in the research study as well.

Report Details:

Psoriasis Therapeutics in Asia-Pacific Markets to 2021: Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth
Published: May, 2015
Pages: 91
Price: US$ 4,995.00

More research studies by the publisher can be found at GBI Research page.


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970